Nevro Corp. (NVRO)
NYSE NYSE Primary Summary
Why Is Nevro (NVRO) Up 0.9% Since Last Earnings Report?
Nevro (NVRO) reported earnings 30 days ago. What's next for the stock?
Here's Why you Should Retain Nevro Stock in Your Portfolio Now
NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 results amid a weak SCS market.
Nevro Q4 Earnings & Revenues Beat Estimates, Gross Margin Down
NVRO's fourth-quarter earnings surpass the Zacks Consensus Estimate, while worldwide revenues decline year over year. The company continues to incur losses at the operating level.
Nevro Corp. Profile
| - Industry | - Sector | Mr. Roderick H. MacLeod CEO | NYSE Exchange | US64157F1030 ISIN |
| US Country | 1,215 Employees | - Last Dividend | 6 Nov 2014 Last Split | 6 Nov 2014 IPO Date |
Overview
Nevro Corp. is a distinguished entity within the medical device industry, focusing on the development and provision of innovative solutions for individuals suffering from chronic pain, both in the United States and internationally. Established in 2006 and having its headquarters in Redwood City, California, Nevro Corp. has set itself apart by offering advanced therapeutic products designed to alleviate chronic back and leg pain without the need for paresthesia. The company leverages its direct sales force alongside a network of sales agents and independent distributors to market its products, ensuring a wide reach to patients in need of their groundbreaking therapies.
Products and Services
Nevro Corp. offers a comprehensive range of products within its HFX spinal cord stimulation (SCS) platform and beyond, catering to the varied needs of patients suffering from chronic pain:
- Senza SCS Implantable Pulse Generator (IPG) System: A cornerstone of Nevro Corp.'s offering, this neuromodulation system employs 10 kHz therapy to treat chronic back and leg pain without inducing paresthesia. The system is evidence-based, highlighting its effectiveness and reliability.
- Senza II and Senza Omnia SCS IPG Systems: Building on the foundation laid by the original Senza system, these iterations offer enhanced features and flexibility, providing patients and healthcare professionals with additional options to tailor the treatment to individual needs.
- Senza HFX iQ Platform: This platform represents a leap forward in patient-centered care, incorporating the HFX iQ implantable pulse generator, the HFX trial stimulator, and the HFX iQ patient remote. It is complemented by the HFX App, which allows for seamless patient control and wireless trialing, further personalizing the pain management experience.
- Sacroiliac Joint Fusion Devices: Nevro Corp. extends its innovative approach to pain management to the sacroiliac joint, offering devices under the NevroV1, NevroFix, and NevroPro brands. These devices are designed to provide relief for patients with pain originating from the sacroiliac joint.
- Surpass Surgical and Percutaneous Leads: Completing its portfolio, Nevro Corp. provides advanced surgical and percutaneous leads, essential components for the effective delivery of neuromodulation therapy. These leads are designed to be both durable and flexible, meeting the high standards required for chronic pain treatments.
